TALEN

TALEN3-ttn.2

ID

ZDB-TALEN-190405-1

Name

TALEN3-ttn.2

Previous Names

None

Target

ttn.2 (1)

Target Sequence 1

5' - TGTGGAGCAACCATGTTCAAAG - 3'

Target Sequence 2

5' - AGGAAATGAATATATA - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
vcc14	ttn.2

Expression

Gene expression in Wild Types + TALEN3-ttn.2

No data available

Phenotype

Phenotype resulting from TALEN3-ttn.2

No data available

Phenotype of all Fish created by or utilizing TALEN3-ttn.2

Phenotype	Fish	Conditions	Figures
myocardium cytosol ab1-myom labeling mislocalised, abnormal	ttn.2^vcc14/vcc14	standard conditions	Fig. 2 from Huttner et al., 2018
heart edematous, abnormal	ttn.2^vcc14/vcc14	standard conditions	Fig. 2 from Huttner et al., 2018
myocardium sarcomere organization decreased process quality, abnormal	ttn.2^vcc14/vcc14	standard conditions	Fig. 2 from Huttner et al., 2018
cardiac ventricle heart contraction decreased process quality, abnormal	ttn.2^vcc14/vcc14	standard conditions	Fig. 2 from Huttner et al., 2018
myocardium Z disc disorganized, abnormal	ttn.2^vcc14/vcc14	standard conditions	Fig. 2 from Huttner et al., 2018
myocardium cytosol ab1-myom labeling increased distribution, abnormal	ttn.2^vcc14/vcc14	standard conditions	Fig. 2 from Huttner et al., 2018
blood circulation decreased occurrence, abnormal	ttn.2^vcc14/vcc14	standard conditions	Fig. 2 from Huttner et al., 2018
whole organism lethal (sensu genetics), abnormal	ttn.2^vcc14/vcc14	standard conditions	Fig. 2 from Huttner et al., 2018
atrium heart contraction decreased process quality, abnormal	ttn.2^vcc14/vcc14	standard conditions	Fig. 2 from Huttner et al., 2018
cardiac ventricle heart contraction decreased occurrence, abnormal	ttn.2^vcc14/+	chemical treatment by environment: phenylhydrazine	Fig. 5 from Huttner et al., 2018
regulation of heart contraction decreased occurrence, abnormal	ttn.2^vcc14/+	chemical treatment by environment: phenylhydrazine	Fig. 5 from Huttner et al., 2018
cardiac ventricle increased size, abnormal	ttn.2^vcc14/+	chemical treatment by environment: phenylhydrazine	Fig. 5 from Huttner et al., 2018
heart nppa expression increased amount, abnormal	ttn.2^vcc14/+	chemical treatment by environment: phenylhydrazine	Fig. 5 from Huttner et al., 2018
cardiac ventricle heart contraction decreased occurrence, abnormal	ttn.2^vcc14/+	control	Fig. 5 from Huttner et al., 2018
atrium increased area, exacerbated	ttn.2^vcc14/+	chemical treatment by environment: phenylhydrazine	Fig. 5 from Huttner et al., 2018
male organism heart contraction decreased process quality, abnormal	ttn.2^vcc14/+	standard conditions	Fig. 3 from Huttner et al., 2018
female organism atrium increased area, abnormal	ttn.2^vcc14/+	standard conditions	Fig. 3 from Huttner et al., 2018
female organism decreased weight, abnormal	ttn.2^vcc14/+	standard conditions	Fig. 3 from Huttner et al., 2018
heart nppb expression increased amount, abnormal	ttn.2^vcc14/+	chemical treatment by environment: phenylhydrazine	Fig. 5 from Huttner et al., 2018
blood hemoglobin decreased amount, abnormal	ttn.2^vcc14/+	chemical treatment by environment: phenylhydrazine	Fig. 5 from Huttner et al., 2018
heart nppa expression decreased amount, abnormal	ttn.2^vcc14/+	control	Fig. 5 from Huttner et al., 2018
atrial myocardium has fewer parts of type atrial myocardium sarcomere, abnormal	ttn.2^vcc14/+	standard conditions	Fig. 4 from Huttner et al., 2018
female organism heart contraction decreased process quality, abnormal	ttn.2^vcc14/+	standard conditions	Fig. 3 from Huttner et al., 2018
ventricular myocardium has fewer parts of type ventricular myocardium sarcomere, abnormal	ttn.2^vcc14/+	standard conditions	Fig. 4 from Huttner et al., 2018

Citations